Likewise, Winter et al. found that IBD patients with normal vitD levels at the initiation of anti-TNF-α therapy had 2.64 folds of increase for remission at 3 months compared to patients with low vitD levels (34). This evidence concerns the gene TNF and inflammatory bowel disease.